Search

Displaying results 9791 - 9800 of 10000 in total
  1. Drug

    CTA30X UCAR-T

    go.drugbank.com/drugs/DB24819
    Investigational

    CTA30X UCAR-T is a biologic drug. CTA30X UCAR-T is under investigation in clinical trial NCT05015972 (UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies).

  2. Drug

    VH3739937

    go.drugbank.com/drugs/DB25287
    Investigational

    VH3739937 is a small molecule drug.

  3. Drug

    SRD-001

    go.drugbank.com/drugs/DB25902
    Investigational

    SRD-001 is a biologic drug.

  4. Drug

    NBQ72S

    go.drugbank.com/drugs/DB26052
    Investigational

    NBQ72S is a small molecule drug. NBQ72S is under investigation in clinical trial NCT06810804 (A Phase IIa Study to Evaluate NBQ72S).

  5. Drug

    Whole Blood

    go.drugbank.com/drugs/DB28492
    Experimental

    Fresh Whole Blood is a biologic drug. Fresh Whole Blood is under investigation in clinical trial NCT03737669 (Mirasol Evaluation of Reduction in Infections Trial).

  6. Drug

    Lutetium Lu 177-DTPA-omburtamab

    go.drugbank.com/drugs/DB31015
    Investigational

    Lutetium Lu 177-DTPA-omburtamab is a radioimmunoconjugate made up of [omburtamab] conjugated with lutetium Lu 177 via the chelating agent of diethylenetriaminepentaacetic acid (DTPA).[L54566]

  7. Drug

    FRAX597

    go.drugbank.com/drugs/DB31734
    Experimental

    FRAX597 is a small molecule drug that inhibits the p21-activated kinases (PAKs).[A274673, A274678]

  8. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it … [A275383] Copper histidinate is a subcutaneously-administered copper-histidine complex that allows for copper supplementation in patients with defective ATP7A transporters.

  9. Drug

    IL21120033

    go.drugbank.com/drugs/DB32508
    Experimental

    IL21120033 is a first-in-class, small-molecule selective CXCR7 agonist.

  10. Drug

    ZKN-013

    go.drugbank.com/drugs/DB32582
    Experimental

    ZKN-013 is a readthrough inducer under investigation for rare dermatological diseases.[L56075]